Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center

Real-World Treatment Patterns and Clinical Outcomes in Radioiodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) Patients Treated with Lenvatinib Monotherapy

November 30th 2022

Dr Worden reviews and discusses real-world data of lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer.